Eculizumab is an FDA approved NMO treatment (Brod, 2020) which inhibits the terminal complement protein C5, preventing cleavage into the proinflammatory C5a and C5b which induce the membrane attack complex (Nishimura et al., 2023). This evidence concerns the gene C5 and neuromyelitis optica.